According to the NCI website, tislelizumab (anti-PD-1 monoclonal antibody BGB-A317) is a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Check for active clinical trials using this agent. (NCI Thesaurus)
Tislelizumab is being studied in more than 25 trials worldwide.They include a Phase III pitting the drug against docetaxel in second-line or third-line NSCLC, expected by early 2021, in addition to trials in hepatocellular carcinoma and esophageal cancer.
More Information in English: